


We claim:

1. A compound according to the structure:



where  $\text{R}^1$  is H, OH, F, Cl, Br, I, a  $\text{C}_1\text{-}\text{C}_6$  optionally substituted alkyl or alkenyl group, an



optionally substituted aryl group or a  $\text{C}-\text{R}_a$  group;

$\text{R}_a$  is a H, OH,  $\text{C}_1\text{-}\text{C}_{10}$ , optionally substituted alkyl or alkenyl group, an optionally substituted O-( $\text{C}_1\text{-}\text{C}_7$  alkyl group) or O-aryl group, an amine group which is optionally substituted with at least one  $\text{C}_1\text{-}\text{C}_{10}$  alkyl group which may be optionally substituted, or a single optionally substituted aryl group, biphenyl group, ( $\text{C}_1\text{-}\text{C}_6$ ) alkylenearyl group, ( $\text{C}_1\text{-}\text{C}_6$ ) alkylenebiphenyl group, heteroaryl group, heterocyclic group, ( $\text{C}_1\text{-}\text{C}_6$ ) alkylene heteroaryl group or ( $\text{C}_1\text{-}\text{C}_6$ ) alkylene heterocyclic group;

$\begin{array}{c} \text{O} \\ \parallel \end{array}$ 
  
 $\text{R}^2$  is a  $\text{C}-\text{R}_b$  group;


$\text{R}_b$  is a H, OH,  $\text{C}_1\text{-}\text{C}_{10}$ , optionally substituted alkyl or alkenyl group, an optionally substituted O-( $\text{C}_1\text{-}\text{C}_7$  alkyl group) or O-aryl group, an amine group which is optionally substituted with at least one  $\text{C}_1\text{-}\text{C}_{10}$  alkyl group which may be optionally substituted, or a single optionally substituted aryl group, biphenyl group, ( $\text{C}_1\text{-}\text{C}_6$ ) alkylenearyl group, ( $\text{C}_1\text{-}\text{C}_6$ ) alkylenebiphenyl group, heteroaryl group, heterocyclic group, ( $\text{C}_1\text{-}\text{C}_6$ ) alkylene heteroaryl group or ( $\text{C}_1\text{-}\text{C}_6$ ) alkylene heterocyclic group;

$\text{R}^3$  and  $\text{R}^6$  are each independently selected from H, OH, F, Cl, Br, I, a  $\text{C}_1\text{-}\text{C}_6$  optionally substituted alkyl or alkenyl group, an optionally substituted aryl group, a carbamate, alkylene carbamate, urethane or alkylene urethane;

$\begin{array}{c} \text{O} \\ \parallel \\ \text{R}^4 \text{ is a } \text{C}-\text{R}_b \text{ group, wherein } \text{R}_b \text{ is as described above; and} \end{array}$

$\begin{array}{c} \text{O} \\ \parallel \\ \text{R}^5 \text{ is a } \text{C}-\text{R}_a \text{ group, wherein } \text{R}_a \text{ is as described above,} \\ \text{with the proviso that at least one of } \text{R}^1 \text{ and } \text{R}^2 \text{ or } \text{R}^4 \text{ and } \text{R}^5 \text{ contains an } \text{R}_a \text{ or } \text{R}_b \text{ group} \\ \text{which is an amine group which is optionally substituted with at least one } \text{C}_1\text{-C}_{10} \text{ alkyl} \\ \text{group which may be optionally substituted, or a single optionally substituted aryl group,} \\ \text{biphenyl group, } (\text{C}_1\text{-C}_6) \text{ alkylenearyl group, } (\text{C}_1\text{-C}_6) \text{ alkylenebiphenyl group, heteroaryl} \\ \text{group, heterocyclic group, } (\text{C}_1\text{-C}_6) \text{ alkylene heteroaryl group or } (\text{C}_1\text{-C}_6) \text{ alkylene} \\ \text{heterocyclic group;} \\ \text{or a stereoisomer, pharmaceutically acceptable salt, solvate, and polymorph thereof.} \end{array}$

2. The compound according to claim 2 wherein said chemical structure is



wherein  $\text{R}_a$  is OH or an optionally substituted O-( $\text{C}_1\text{-C}_7$  alkyl group) or O-aryl group; and  $\text{R}_b$  is an amine group which is optionally substituted with at least one  $\text{C}_1\text{-C}_{10}$  alkyl group which may be optionally substituted, or an optionally substituted aryl group, biphenyl group, ( $\text{C}_1\text{-C}_6$ ) alkylenearyl group, ( $\text{C}_1\text{-C}_6$ ) alkylenebiphenyl group, heteroaryl group, heterocyclic group, ( $\text{C}_1\text{-C}_6$ ) alkylene heteroaryl group or ( $\text{C}_1\text{-C}_6$ ) alkylene heterocyclic group.

3. The compound according to claim 2 having the chemical structure:



4. The compound according to claim 1 wherein  $\text{R}_a$  is an optionally substituted  $\text{O}-(\text{C}_1\text{-}\text{C}_7)$  alkyl group or  $\text{O}$ -aryl group.
5. The compound according to claim 2 wherein  $\text{R}_a$  is an optionally substituted  $\text{O}-(\text{C}_1\text{-}\text{C}_7)$  alkyl group or  $\text{O}$ -aryl group.
6. The compound according to claim 3 wherein  $\text{R}_a$  is an optionally substituted  $\text{O}-(\text{C}_1\text{-}\text{C}_7)$  alkyl group or  $\text{O}$ -aryl group.
7. The compound according to claim 1 wherein  $\text{R}_b$  is an amine group which is optionally substituted with at least one  $\text{C}_1\text{-}\text{C}_{10}$  alkyl group which may be optionally substituted, or a single optionally substituted aryl group, biphenyl group,  $(\text{C}_1\text{-}\text{C}_6)$  alkylenearyl group,  $(\text{C}_1\text{-}\text{C}_6)$  alkylenebiphenyl group, heteroaryl group, heterocyclic group,  $(\text{C}_1\text{-}\text{C}_6)$  alkylene heteroaryl group or  $(\text{C}_1\text{-}\text{C}_6)$  alkylene heterocyclic group.
8. The compound according to claim 3 wherein  $\text{R}_b$  is an amine group which is optionally substituted with at least one  $\text{C}_1\text{-}\text{C}_{10}$  alkyl group which may be optionally substituted, or a single optionally substituted aryl group, biphenyl group,  $(\text{C}_1\text{-}\text{C}_6)$  alkylenearyl group,  $(\text{C}_1\text{-}\text{C}_6)$  alkylenebiphenyl group, heteroaryl group, heterocyclic group,  $(\text{C}_1\text{-}\text{C}_6)$  alkylene heteroaryl group or  $(\text{C}_1\text{-}\text{C}_6)$  alkylene heterocyclic group.
9. The compound according to claim 4 wherein  $\text{R}_b$  is an amine group which is optionally substituted with at least one  $\text{C}_1\text{-}\text{C}_{10}$  alkyl group which may be optionally substituted, or a single optionally substituted aryl group, biphenyl group,  $(\text{C}_1\text{-}\text{C}_6)$  alkylenearyl group,  $(\text{C}_1\text{-}\text{C}_6)$  alkylenebiphenyl group, heteroaryl group, heterocyclic group,  $(\text{C}_1\text{-}\text{C}_6)$  alkylene heteroaryl group or  $(\text{C}_1\text{-}\text{C}_6)$  alkylene heterocyclic group.

10. The compound according to claim 1 wherein R<sub>a</sub> is an optionally substituted O-(C<sub>1</sub>-C<sub>7</sub> alkyl group) and R<sub>b</sub> is an amine group which is optionally substituted with at least one C<sub>1</sub>-C<sub>10</sub> alkyl group which may be optionally substituted, or a single optionally substituted aryl group, biphenyl group, (C<sub>1</sub>-C<sub>6</sub>) alkylenearyl group, (C<sub>1</sub>-C<sub>6</sub>) alkylenebiphenyl group, heteroaryl group, heterocyclic group, (C<sub>1</sub>-C<sub>6</sub>) alkylene heteroaryl group or (C<sub>1</sub>-C<sub>6</sub>) alkylene heterocyclic group.
11. The compound according to claim 1 wherein R<sub>b</sub> is an amine group which is optionally substituted with a single cyclohexyl group, an optionally substituted phenyl group, or an optionally substituted benzyl group and R<sub>a</sub> is a O-(C<sub>1</sub>-C<sub>3</sub> alkyl) group or an O-phenyl group.
12. The compound according to claim 2 wherein R<sub>b</sub> is an amine group which is optionally substituted with a single cyclohexyl group, an optionally substituted phenyl group, or an optionally substituted benzyl group and R<sub>a</sub> is a O-(C<sub>1</sub>-C<sub>3</sub> alkyl) group or an O-phenyl group.
13. The compound according to claim 3 wherein R<sub>b</sub> is an amine group which is optionally substituted with a single cyclohexyl group, an optionally substituted phenyl group, or an optionally substituted benzyl group and R<sub>a</sub> is a O-(C<sub>1</sub>-C<sub>3</sub> alkyl) group or an O-phenyl group.
14. A pharmaceutical composition comprising an effective amount of a compound according to claim 1 in combination with a pharmaceutically acceptable carrier, additive or excipient.
15. A pharmaceutical composition comprising an effective amount of a compound according to claim 2 in combination with a pharmaceutically acceptable carrier, additive or excipient.

16. A pharmaceutical composition comprising an effective amount of a compound according to claim 3 in combination with a pharmaceutically acceptable carrier, additive or excipient.
17. A pharmaceutical composition comprising an effective amount of a compound according to claim 4 in combination with a pharmaceutically acceptable carrier, additive or excipient.
18. A pharmaceutical composition comprising an effective amount of a compound according to claim 5 in combination with a pharmaceutically acceptable carrier, additive or excipient.
19. A pharmaceutical composition comprising an effective amount of a compound according to claim 6 in combination with a pharmaceutically acceptable carrier, additive or excipient.
20. A pharmaceutical composition comprising an effective amount of a compound according to claim 7 in combination with a pharmaceutically acceptable carrier, additive or excipient.
21. A pharmaceutical composition comprising an effective amount of a compound according to claim 8 in combination with a pharmaceutically acceptable carrier, additive or excipient.
22. A pharmaceutical composition comprising an effective amount of a compound according to claim 9 in combination with a pharmaceutically acceptable carrier, additive or excipient.
23. A pharmaceutical composition comprising an effective amount of a compound according to claim 10 in combination with a pharmaceutically acceptable carrier, additive or excipient.


24. A pharmaceutical composition comprising an effective amount of a compound according to claim 11 in combination with a pharmaceutically acceptable carrier, additive or excipient.

25. A pharmaceutical composition comprising an effective amount of a compound according to claim 12 in combination with a pharmaceutically acceptable carrier, additive or excipient.

26. A pharmaceutical composition comprising an effective amount of a compound according to claim 13 in combination with a pharmaceutically acceptable carrier, additive or excipient.

27. A method of treating a tumor or cancer in a patient in need of such treatment comprising administering to said patient an effective amount of a compound according to any of claims 1-13.

28. A method of treating a hyperproliferative disease in a patient in need thereof comprising administering to said patient an effective amount of a compound according to the chemical structure:



where  $R^1$  is H, OH, F, Cl, Br, I, a  $C_1-C_6$  optionally substituted alkyl or alkenyl group, an

optionally substituted aryl group or a  $\begin{array}{c} O \\ || \\ C-R_a \end{array}$  group;

$R_a$  is a H, OH,  $C_1-C_{10}$ , optionally substituted alkyl or alkenyl group, an optionally substituted  $O-(C_1-C_7)$  alkyl group) or O-aryl group, an amine group which is optionally

substituted with at least one C<sub>1</sub>-C<sub>10</sub> alkyl group which may be optionally substituted, or a single optionally substituted aryl group, biphenyl group, (C<sub>1</sub>-C<sub>6</sub>) alkylenearyl group, (C<sub>1</sub>-C<sub>6</sub>) alkylenebiphenyl group, heteroaryl group, heterocyclic group, (C<sub>1</sub>-C<sub>6</sub>) alkylene heteroaryl group or (C<sub>1</sub>-C<sub>6</sub>) alkylene heterocyclic group;

$$\begin{array}{c} \text{O} \\ \parallel \\ \text{R}^2 \text{ is a C-} \text{R}_b \text{ group;} \end{array}$$

R<sub>b</sub> is a H, OH, C<sub>1</sub>-C<sub>10</sub>, optionally substituted alkyl or alkenyl group, an optionally substituted O-(C<sub>1</sub>-C<sub>7</sub> alkyl group) or O-aryl group, an amine group which is optionally substituted with at least one C<sub>1</sub>-C<sub>10</sub> alkyl group which may be optionally substituted, or a single optionally substituted aryl group, biphenyl group, (C<sub>1</sub>-C<sub>6</sub>) alkylenearyl group, (C<sub>1</sub>-C<sub>6</sub>) alkylenebiphenyl group, heteroaryl group, heterocyclic group, (C<sub>1</sub>-C<sub>6</sub>) alkylene heteroaryl group or (C<sub>1</sub>-C<sub>6</sub>) alkylene heterocyclic group;

R<sup>3</sup> and R<sup>6</sup> are each independently selected from H, OH, F, Cl, Br, I, a C<sub>1</sub>-C<sub>6</sub> optionally substituted alkyl or alkenyl group, an optionally substituted aryl group, a carbamate, alkylene carbamate, urethane or alkylene urethane;

$$\begin{array}{c} \text{O} \\ \parallel \\ \text{R}^4 \text{ is a C-} \text{R}_b \text{ group, wherein R}_b \text{ is as described above; and} \end{array}$$

$$\begin{array}{c} \text{O} \\ \parallel \\ \text{R}^5 \text{ is a C-} \text{R}_a \text{ group, wherein R}_a \text{ is as described above,} \end{array}$$
  
 with the proviso that at least one of R<sup>1</sup> and R<sup>2</sup> or R<sup>4</sup> and R<sup>5</sup> contains an R<sub>a</sub> or R<sub>b</sub> group which is an amine group which is optionally substituted with at least one C<sub>1</sub>-C<sub>10</sub> alkyl group which may be optionally substituted, or a single optionally substituted aryl group, biphenyl group, (C<sub>1</sub>-C<sub>6</sub>) alkylenearyl group, (C<sub>1</sub>-C<sub>6</sub>) alkylenebiphenyl group, heteroaryl group, heterocyclic group, (C<sub>1</sub>-C<sub>6</sub>) alkylene heteroaryl group or (C<sub>1</sub>-C<sub>6</sub>) alkylene heterocyclic group;  
 or a stereoisomer, pharmaceutically acceptable salt, solvate, and polymorph thereof.

29. The method according to claim 28 wherein said hyperproliferative disease is psoriasis, genital warts, hyperkeratosis, ichthyosis, keratoderma or lichen planus.
30. A method of inhibiting a cellular kinase in cells of a patient comprising exposing said cells to an effective amount of a compound according to claim 1.